Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Current Oncology (Toronto, Ont.)|February 26, 2026
Immune-Related Thyroid Dysfunction in PD-L1 High Non-Oncogene-Addicted NSCLC Treated with First-Line Pembrolizumab: Incidence, Timing, and Predictive ImpactFilip Marković, Mihailo Stjepanović, Milica Kontić
Current Issues in Molecular Biology|July 23, 2025
Hypermethylation of SOX1 and HOXA9 Genes Is Associated with Clinicopathologic Characteristics of Non-Small Cell Lung Cancer PatientsMilica Kontić, Mihailo Stjepanović, Filip Marković
Current Oncology (Toronto, Ont.)|May 26, 2026
Clinical Outcomes and Immune-Related Adverse Events in Metastatic Non-Squamous NSCLC Treated with First-Line Pembrolizumab-Chemotherapy: A Real-World Study from SerbiaZlatan Bojić, Filip Marković, Milica Kontić
Cancers|April 14, 2026
Real-World Comparison of PD-1 and PD-L1 Inhibitor Monotherapy in Metastatic Non-Small Cell Lung Cancer with High PD-L1 ExpressionFilip Marković, Zlatan Bojić, Mihailo Stjepanović, et al.
Cancers|September 14, 2024
The Association of Immune-Related Adverse Events with the Efficacy of Atezolizumab in Previously Treated Advanced Non-Small-Cell Lung Cancer Patients: A Single-Center ExperienceFilip Marković, Mihailo Stjepanović, Natalija Samardžić, et al.
Acta Clinica Croatica|September 30, 2021
UNUSUAL CLINICAL COURSE OF NEUROSARCOIDOSIS MANIFESTED WITH ACUTE HYDROCEPHALUSDragana Jovanović, Dana Grujičić, Mihailo Stjepanović, et al.
Current Oncology (Toronto, Ont.)|June 25, 2025
KRAS Mutations as Predictive Biomarkers for First-Line Immune Checkpoint Inhibitor Monotherapy in Advanced NSCLC: A Systematic Review and Meta-AnalysisFilip Marković, Jelena Milin-Lazović, Nikola Nikolić, et al.
Cancers|July 12, 2025
The Efficacy of First-Line Pembrolizumab Monotherapy in Patients with Metastatic NSCLC Aged ≥70 Years with High PD-L1 (TPS ≥ 50%) Expression: A Multicenter Real-World StudyFilip Marković, Maximilian Hochmair, Nino Müser, et al.
Cancers|November 9, 2024
Efficacy of Atezolizumab in Subsequent Lines of Therapy for NSCLC Patients: Insights from Real-World DataMilica Kontić, Filip Marković, Nikola Nikolić, et al.
Wiener Medizinische Wochenschrift (1946)|July 26, 2015
Impact of HER2 codon 655 polymorphism and expression of HER2 and HER3 in non small cell lung cancer patientsJulian Ananiev, Elina Aleksandrova, Desislava Skerleva, et al.
Pageof 2